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Abstract The ehemokine RANTES has been implicated in the 
pathogenesis of allergic inflammatory diseases including asthma 
and rhinitis which are frequently treated with glucocorticoids. 
We observed that dexamethasone dramatically inhibited 
RANTES mRNA expression dose dependently in anti-CD3 
activated Hut-78 T cells and human PBMCs. Inhibition of 
RANTES expression did not appear to be secondary to IL-2 
inhibition and required binding to the intracellular glucocorticoid 
receptor. The down-regulation of RANTES expression by 
glucocorticoids in T cells may directly contribute to the efficacy 
of these agents in suppressing cellular infiltration and to their 
anti-inflammatory properties. 
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1. Introduction 
The pathogenesis of allergy and asthma is clearly associated 
with the release of proinflammatory mediators from eosino- 
phils and other inflammatory cells recruited to the site of 
allergic inflammation. Although tissue infiltration by large 
numbers of eosinophils is well recognized, the processes that 
control eosinophil recruitment are not fully understood. Re- 
cently, the cytokine RANTES ~egulated upon activation, 
normal T cell expressed and secreted), a member of the C-C 
~amily of chemokines, has been implicated as a pivotal me- 
diator of eosinophil recruitment and subsequent inflammation 
[1]. The RANTES gene encodes an 8-kDa cytokine with po- 
tent chemotactic activity for eosinophils, basophils, mono- 
cytes, NK  cells, and CD45RO + 'memory' CD4 + T cells 
[2,3]. Diverse proinflammatory actions of RANTES include 
activation of eosinophils and T cells [4,5], adhesion of T cells 
to activated endothelium [6], and release of histamine from 
basophils [7]. Since RANTES is present at high levels in as- 
sociation with eosinophil-rich infiltrate in nasal polyps [8] and 
the bronchial epithelium of mild asthmatics [9], both clinical 
and biochemical data support a potentially critical role for 
RANTES in allergic inflammation. 
Multiple cell types including macrophages, mast cells, fibro- 
blasts, and tubular epithelial cells appear to contribute to an 
initial and transient production of RANTES at the sites of 
allergic inflammation [6,10]. T lymphocytes are then recruited 
to the area where they become activated by their cognate 
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antigen and subsequently produce large and sustained levels 
of RANTES thereby amplifying and maintaining the inflam- 
matory response. Thus, understanding the mechanisms that 
regulate RANTES expression in T lymphocytes may provide 
valuable insights for the therapeutic manipulation of allergic 
inflammation. 
Anti-inflammatory therapy with glucocorticoids i of criti- 
cal importance in the treatment of asthma. Although gluco- 
corticoids are recognized to have anti-inflammatory effects 
including inhibition of cytokine and lymphokine xpression 
(reviewed in [11]), reduction of T cell proliferation [12], and 
inhibition of eosinophil infiltration [13], the molecular basis 
for these pluripotent effects are not well characterized. In this 
study, we examined the effect of glucocorticoid treatment on 
RANTES expression in T cells and observed that expression 
in both anti-CD3 activated and resting T cells is dramatically 
inhibited by dexamethasone. 
2. Materials and methods 
2.1. Cell culture and reagents 
The Hut-78 cell line was obtained through the American Type 
Tissue Collection (ATCC TIB 161), Rockville, MD. Cells were cul- 
tured in RPMI supplemented with 10% FCS (Sigma, St. Louis, MO), 
100 U/ml penicillin, 100 I.tg/ml streptomycin, 2 mM glutamine, and 15 
mM HEPES. PBMCs and Hut-78 cells were typically maintained at 
4-6 × 105 cells/ml and were activated using immobilized OKT3 (anti- 
CD3) monoclonal ntibody (ATCC, Rockville, MD) at 30 p,g/100 mm 
tissue culture plate per 3 x 106 cells. Cells were also treated with vary- 
ing concentrations of Dex (1-100 nM) (Sigma, St. Louis, MO), IL-2 
(100 U/ml) (Biological Response Modifiers Group, NCI, Frederick, 
MD), and RU 40555 (1 ~tM) (Roussell Uclaf, Romainville, France). 
2.2. Isolation of PBMCs 
Peripheral blood mononuclear cells (PBMC) were isolated by den- 
sity gradient separation using Histopaque according to the manufac- 
turer's protocol (Sigma, St. Louis, MO) from whole blood donated 
from volunteers (American Red Cross Blood Bank, Boise, ID). Lym- 
phocytes were depleted of monocytes by plastic adherence as pre- 
viously described [14]. Purity of lymphocyte populations was deter- 
mined by Wright Giemsa staining and preparations typically 
contained > 85% lymphocytes. Viability was > 98% as assessed by 
trypan blue dye exclusion. 
2.3. RNA isolation and Northern blot analysis 
Total cellular RNA was isolated from cell samples (3 X 10 6) using 
the guanidinium isothiocyanate (GITC)/cesium chloride method [15]. 
Briefly, cells were solubilized in 4 M GITC and overlaid on a 5.7 M 
CsC1 cushion. Samples were ultracentrifuged at 150000×g for 17 h. 
The RNA pellet was resuspended, ethanol precipitated and quanti- 
tated. RNA (20 ~tg) was denatured in 4 × sample buffer and electro- 
phoresed in a 1.25% agarose-formaldehyde gel [15]. The gel was trans- 
ferred to a nylon membrane and the nucleic acids immobilized by UV 
cross-linking. The filters were prehybridized at 42°C for 4 h in 50% 
formamide, 5x SSC, 50 mM potassium phosphate pH 8.0, 5 x Den- 
hardts' solution and 100 ~tg/ml denatured salmon sperm DNA. Hy- 
bridizations were performed at 42°C for 18 h in the above solution 
substituting 20 mM potassium phosphate pH 6.5 and 1 X Denhardts' 
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solution, and adding 2×106 cpm of radiolabeled probe per ml of 
solution. Filters were sequentially h bridized with a a2P-labeled 410 
bp EcoRIIApaI RANTES probe (ATCC) and the human GAPDH 
eDNA (ATCC). Blots were washed in 0.1 XSSC and 0.1% SDS at 
60°C and exposed to X-ray film. Equivalent loading of RNA was 
determined by ethidium bromide staining of ribosomal RNA and by 
detection of GAPDH transcripts on Northern blots. 
3. Results 
3.1. T cell Ag receptor engagement rapidly induces RANTES 
expression in T cells 
Antigen-dependent T cell activation is induced by the inter- 
action of the CD3 component of the T cell receptor with an 
appropriately presented antigen [16]. CD3 receptor signaling 
can also be initiated using immobilized anti-CD3 (OKT3) 
antibodies. We examined whether CD3-mediated signaling al- 
ters the expression of RANTES using the Hut-78 T cell line as 
an initial model system. This CD4 + cell line was derived from 
a cutaneous T cell lymphoma nd expresses a 'mature' T cell 
phenotype demonstrated by constitutive xpression of IL-2 
and IL-2 receptors [17]. We observed that the activation of 
Hut-78 cells with immobilized anti-CD3 antibody results in a 
rapid induction of RANTES mRNA (Fig. 1A) with a 7-fold 
increase over constitutive xpression. In contrast o the late 
transcriptional increases previously described using peripheral 
T cells [18], dramatically elevated levels of RANTES message 
were observed as early as 3 h post receptor ligation. 
Although the Hut-78 cell line constitutively expresses mod- 
erate levels of both IL-2 and IL-2 receptor, this cell line is 
responsive to exogenous IL-2 both in terms of cytokine pro- 
duction and proliferation [17]. To determine whether in- 
creased IL-2 production caused by CD3 receptor ligation 
[19] is responsible for up-regulation of RANTES expression, 
unactivated cells were treated for 24 h with 100 U/ml IL-2. As 
shown in Fig. 1B, IL-2 treatment fails to upregulate RANTES 
expression demonstrating the involvement of distinct CD3 
receptor mediated pathways in RANTES up-regulation. The 
ineffectiveness of IL-2 in altering the expression of RANTES 
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Fig. 1. Time course of RANTES expression i anti-CD3 activated 
Hut-78 ceils. (A) Hut-78 cells were stimulated with immobilized 
OKT3 antibody for 0, 3, or 24 h and the level of RANTES mRNA 
determined by Northern analysis. (B) Cells were cultured for 24 h 
in either complete media (lane 1), in the presence of immobilized 
OKT3 antibody (lane 2), or with 100 U/ml of IL-2 (lane 3) as indi- 
cated and RNA expression analyzed by Northern blots. Equivalent 
RNA loading was verified by re-probing with GAPDH and moni- 
toring rRNA fluorescence intensity (not shown). Representative 
autoradiograms are presented. 
3.2. Dexamethasone inhibits constitutive and anti-CD3 
inducible RANTES expression 
Because glucocorticoids are commonly used in the treat- 
ment of allergic diseases in which RANTES may be of patho- 
logic significance, the effect of DEX on RANTES expression 
in unactivated and activated T lymphocytes was examined. As 
shown in Fig. 2A, 24 h treatment with 100 nM DEX drama- 
tically decreased RANTES expression in unactivated Hut-78 
cells. Expression of RANTES in Hut-78 cells stimulated with 
anti-CD3 antibody for 24 h was also inhibited by 100 nM 
DEX (Fig. 2B). Dexamethasone had no effect on either con- 
stitutive or anti-CD3 stimulated RANTES expression when 
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Fig. 2. Dexamethasone i hibits the expression of RANTES in human T cells. Unactivated Hut-78 cells (A), 24 h anti-CD3 activated Hut-78 
cells (B), 3 h anti-CD3 activated Hut-78 cells (C), and 40 h anti-CD3 plus IL-2 treated human PBMCs (D) were concurrently treated with dex- 
amethasone (100 nM) or vehicle for various time as indicated and RANTES expression determined by Northern analysis. Equivalent RNA 
loading was verified by re-probing with GAPDH and representative autoradiograms are presented. 
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Fig. 3. Dose response of Dex mediated inhibition of RANTES ex- 
pression. Hut-78 cells were activated with anti-CD3 antibody and 
concurrently treated with increasing concentrations of Dex as indi- 
cated. After 24 h of culture, RANTES mRNA expression was deter- 
mined by Northern analysis. Equivalent RNA loading was verified 
by re-probing with GAPDH and representative autoradiograms are 
presented. 
dexamethasone and anti-CD3 exposure was limited to 3 h 
(Fig. 2C). These slow kinetics of action suggest hat the in- 
hibitory properties of DEX on RANTES expression require 
de novo protein synthesis. 
To determine whether DEX also inhibits RANTES expres- 
sion in primary lymphocytes, human PBMCs were activated 
with anti-CD3 plus IL-2 and cultured in the presence or ab- 
sence of 100 nM DEX for 40 h. Viability in DEX-treated cells 
was assessed via trypan blue dye exclusion to be > 90%. We 
observed a dramatic and long-lasting down-regulation of 
RANTES expression clearly visible in 40 h treated cells 
(Fig. 2D). Because DEX can decrease IL-2 production, experi- 
ments were performed to determine whether decreased 
RANTES expression was secondary to the effects of decreased 
IL-2. We observed that DEX inhibited RANTES expression 
in anti-CD3 activated PBMCs in either the presence (Fig. 2) 
or absence of exogenous IL-2 (unpublished ata). 
3.3. Inhibition of  RANTES expression by DEX is 
concentration-dependent and requires binding to the 
GC receptor 
To determine the minimum concentration of DEX required 
to inhibit RANTES expression, various amounts of DEX 
were added to Hut-78 cells for 24 h at the time of T cell 
activation. As shown in Fig. 3, dose-dependent i hibition of 
RANTES expression was observed with diminished RANTES 
expression observable with concentrations a low as 1 nM. 
To determine whether the inhibitory activity of DEX on 
RANTES expression requires binding to its intracellular re- 
ceptor, we evaluated the effects of the steroid hormone an- 
tagonist RU40555. Incubation of Hut-78 cells with RU40555 
did not significantly alter the expression of RANTES (Fig. 4). 
However, RU40555 dramatically abrogated the inhibitory ef- 
fects of 100 nM DEX indicating a mechanism requiring the 
formation of a functional DEX-GC receptor complex. 
4. Discussion 
These studies provide the first demonstration that expres- 
sion of the RANTES gene in human T cells is sensitive to 
inhibition by glucocorticoids. We observed that DEX treat- 
ment dose-dependently suppresses RANTES mRNA expres- 
sion in both unactivated and antigen-receptor activated 
PBMCs and Hut-78 cells. This dramatic inhibition was found 
to result typically in a 66% and 64% decrease relative to the 
level of expression observed in activated control Hut-78 cells 
and PBMCs, respectively. Decreased RANTES was observed 
with concentrations a  low as 1 nM which is well within in 
vivo concentrations expected following systemic glucocorti- 
coid administration. Given the pivotal role of RANTES in 
allergic conditions associated with eosinophil infiltration, the 
inhibitory effects of DEX on RANTES expression may be 
intimately linked to the anti-inflammatory properties of glu- 
cocorticoids and to their clinical effectiveness in controlling 
airway inflammation. 
At present, the specific biochemical and molecular mecha- 
nisms of RANTES inhibition by DEX remain unclear. How- 
ever, our results indicate that mechanisms independent of de- 
creased IL-2 production caused by DEX treatment are 
responsible for suppression of RANTES expression as exog- 
enous IL-2 failed to alter the inhibitory effects of DEX. It 
is plausible that glucocorticoid inhibition may be mediated 
through ~¢B-like sites previously implicated in the control of 
RANTES transcription [20,21]. It has recently been shown 
that glucocorticoids activate IKB [22], an inhibitor of the 
~B-family of transcription factors, and may prevent he ~¢B- 
family of transcription factors from up-regulating RANTES 
expression. These potential mechanisms of glucocorticoid ac- 
tion remain an important area for future work. 
We have observed that RANTES mRNA is markedly and 
rapidly induced (3 h) following anti-CD3 activation (Fig. 1A) 
in Hut-78 cells compared to the late up-regulation (days 3-7) 
initially reported for primary T cells following antigen recep- 
tor signaling. Immediate-early induction kinetics of RANTES 
has also been observed in other cell types including macro- 
phages, fibroblasts, and epithelial cells [6,10]. Recent data 
suggest he immediate-early induction of RANTES observed 
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Fig. 4. The glucocorticoid receptor antagonist RU40555 prevents in- 
hibition of RANTES expression by Dex. Hut-78 cells were activated 
with anti-CD3 antibody and concurrently treated with Dex (100 
nM) and/or RU40555 (I ~tM). After 24 h of culture, RANTES 
mRNA expression was determined by Northern analysis. Equivalent 
RNA loading was verified by re-probing with GAPDH and repre- 
sentative autoradiograms are presented. 
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mediated through the Rel heterodimers p50-p65 transcription 
factors [21]. These factors have been shown to be transiently 
induced early in T cell activation [23] and may also be in- 
volved in the immediate-early induction of RANTES expres- 
sion in activated Hut-78 cells. Interestingly, it appears that 
these factors do not function analogously during the initial 
stages of primary T cell activation [21] as demonstrated by the 
characteristic absence of early RANTES expression suggesting 
the involvement of distinct elements in the delayed up-regula- 
tion of primary T cells. Given the importance of RANTES in 
the pathogenesis of both allergic inflammation and AIDS [24], 
the comparison and identification of the DNA-binding factors 
causing the early up-regulation of RANTES in Hut-78 T cells 
compared to the very late up-regulation i  primary T cells 
following antigen receptor ligation should provide important 
information for understanding the control of RANTES ex- 
pression and potentially impact the therapy of a variety of 
disease states. The mechanisms of RANTES up-regulation 
and glucocorticoid inhibition may be of main importance 
and are clearly relevant in the very common therapeutic use 
of glucocorticoids. 
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